CTRI/2018/02/012109已完成1 期
A Phase I, Multiple dose, Placebo controlled parallel group double blind study to evaluate the safety and tolerability of Spironolactone 5% topical cream in Healthy adult male subject.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) BMI: 18.5 to 30.0 kg/m2, both inclusive.
- •2) Able to give written informed consent to participate in the study.
- •3) Non-smokers and non-tobacco users (i.e. having no history of smoking and tobacco consumption for at least one year prior to study)
- •4) All volunteers must be judged by the principal or sub-investigator as normal and healthy during a pre-study safety assessment performed within 14 days of the first dose of cream application which will include:
- •a) A physical examination with no clinically significant finding.
- •b) Results within normal limits or clinically non-significant for the laboratory tests.
- •- Additional tests and/or examinations may be performed, if necessary, based on Principal Investigator discretion.
- •- All results will be assessed against the current laboratory normal ranges at the time of testing and a copy of the normal ranges used will be included in the study documentation.
排除标准
- •Volunteers must not be enrolled in the study if they meet any one of the following criteria:
- •1) History of allergic responses to Spironolactone or other related drugs, or any of its formulation ingredients.
- •2) Volunteer has tattoo, mark of injury/surgery, any discolouration of skin, any other birth mark on application area of skin, any ongoing skin disease or history of frequent skin disease, damaged skin at application sites or has cracks/hardening/scarring at the application site
- •3) Volunteer has excessive hair at the application site
- •4) Presence of open sores, or other skin abnormalities at the application site
- •5) Have significant diseases or clinically significant abnormal findings during screening [medical history, physical examination, laboratory evaluations, ECG and chest X-ray recording].
- •6) Use of enzyme-modifying drugs [i.e. strong CYP3A inhibitors such as boceprevir, cobicistat, conivaptan, danoprevir and ritonavir, elvitegravir and ritonavir, grapefruit juice, indinavir and ritonavir, itraconazole, ketoconazole, lopinavir and ritonavir, paritaprevir and ritonavir and (ombitasvir and/or dasabuvir), posaconazole, ritonavir, saquinavir and ritonavir, telaprevir, tipranavir and ritonavir, troleandomycin, voriconazole and strong CYP3A inducers such as carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. Johnââ?¬•s wort etc.] within 30 days prior to the first dose of cream application.
- •7) History or evidence of drug dependence or of alcoholism.
- •8) History of difficulty with donating blood or difficulty in accessibility of veins.
- •9) Volunteers who have received a known Investigational drug within ten elimination half life of the administered drug or within 30 days prior to cream application, whichever is greater.
- •10) Use of Topical analgesic or antihistaminic cream within 14 days prior to first dose of cream application.
- •11) Any food allergy, intolerance, restriction or special diet that, in the opinion of the Principal Investigator or Sub-Investigator, could contraindicate the volunteerââ?¬•s participation in this study.
- •12) Institutionalized volunteer (having no association with Cliantha Research Limited, i.e. Employee).
- •13) Use of medicine [prescribed and over the counter (OTC) medication including herbal remedies] at any time within 14 days prior to first dose of cream application.
- •14) Found positive in urine test for drugs of abuse and/or alcohol breath test done before check-in.
- •15) Consumption of grapefruit or grape fruit products within 7 days prior to the first dose of cream application.
研究者
相似试验
进行中（未招募）
1 期
Phase 2 Study of AMG 785 in Postmenopausal Women With Low Bone Mineral DensityPostmenopausal osteoporosisEUCTR2008-005991-28-ATAmgen Inc400
进行中（未招募）
不适用
Phase 2 Study of AMG 785 in Postmenopausal Women With Low Bone Mineral DensityMedDRA version: 14.1Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPostmenopausal osteoporosisEUCTR2008-005991-28-BEAmgen Inc400
进行中（未招募）
1 期
A Randomized, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women with Low Bone Mineral Density / Estudio de fase 2 aleatorizado, controlado con placebo, de dosis múltiple para determinar la eficacia, la seguridad y la tolerabilidad de AMG 785 en el tratamiento de mujeres posmenopáusicas con baja densidad mineral óseaPostmenopausal osteoporosis / Osteoporosis postmenopáusicaMedDRA version: 9.1Level: LLTClassification code 10031285Term: Osteoporosis postmenopausalEUCTR2008-005991-28-ESAmgen Inc419
进行中（未招募）
不适用
Phase 2 Study of AMG 785 in Postmenopausal Women With Low Bone Mineral DensityPostmenopausal osteoporosisEUCTR2008-005991-28-DKAmgen Inc400
已完成
1 期
A Phase 1, placebo and positive-controlled, dose-escalation study to determine the safety, pharmacodynamics and pharmacokinetics of a single intravenous injection ofHSK3486 in healthy subjects.AnesthesiaAnaesthesiology - AnaestheticsACTRN12614000428662Sichuan Haisco Pharmaceutical Co., Ltd.48